A new drug has been found to be effective in treating complicated urinary tract infections. The drug, which is called solithromycin, is a member of the macrolide class of antibiotics. It is the only member of this class that is currently approved by the FDA for the treatment of complicated urinary tract infections.
In a study of 784 patients with complicated urinary tract infections, solithromycin was found to be superior to levofloxacin, the current standard of care, in both the cure rate and the time to cure. Solithromycin was also found to be well-tolerated, with a similar safety profile to that of levofloxacin.
The findings of this study suggest that solithromycin may be an effective alternative to levofloxacin for the treatment of complicated urinary tract infections.
A new drug has been found to be effective in treating complicated urinary tract infections. The drug, called ceftazidime-avibactam, was found to be effective in a phase III clinical trial. The trial involved 728 patients with complicated urinary tract infections, and the drug was found to be effective in treating the infection in all patients. The drug is a cephalosporin antibiotic, and it is believed to be effective because it is able to penetrate the bacterial cell wall and kill the bacteria. The drug is currently being reviewed by the FDA, and it is expected to be available for use in the United States in the near future.
